Suppr超能文献

比较有和没有进展期结直肠肿瘤的筛查参与者不同类型液体活检中的代谢组学图谱。

Comparing Metabolomics Profiles in Various Types of Liquid Biopsies among Screening Participants with and without Advanced Colorectal Neoplasms.

作者信息

Erben Vanessa, Poschet Gernot, Schrotz-King Petra, Brenner Hermann

机构信息

Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany.

Medical Faculty Heidelberg, Heidelberg University, 69120 Heidelberg, Germany.

出版信息

Diagnostics (Basel). 2021 Mar 20;11(3):561. doi: 10.3390/diagnostics11030561.

Abstract

Analysis of metabolomics has been suggested as a promising approach for early detection of colorectal cancer and advanced adenomas. We investigated and compared the metabolomics profile in blood, stool, and urine samples of screening colonoscopy participants and aimed to evaluate differences in metabolite concentrations between people with advanced colorectal neoplasms and those without neoplasms. Various types of bio-samples (plasma, feces, and urine) from 400 participants of screening colonoscopy were investigated using the MxP Quant 500 kit (Biocrates, Innsbruck, Austria). We detected a broad range of metabolites in blood, stool, and urine samples (504, 331, and 131, respectively). Significant correlations were found between concentrations in blood and stool, blood and urine, and stool and urine for 93, 154, and 102 metabolites, of which 68 (73%), 126 (82%), and 39 (38%) were positive correlations. We found significant differences between participants with and without advanced colorectal neoplasms for concentrations of 123, 49, and 28 metabolites in blood, stool and urine samples, respectively. We detected mostly positive correlations between metabolite concentrations in blood samples and urine or stool samples, and mostly negative correlations between urine and stool samples. Differences between subjects with and without advanced colorectal neoplasms were found for metabolite concentrations in each of the three bio-fluids.

摘要

代谢组学分析已被认为是早期检测结直肠癌和晚期腺瘤的一种有前景的方法。我们调查并比较了结肠镜筛查参与者血液、粪便和尿液样本中的代谢组学特征,旨在评估晚期结直肠肿瘤患者与无肿瘤患者之间代谢物浓度的差异。使用MxP Quant 500试剂盒(奥地利因斯布鲁克的Biocrates公司)对400名结肠镜筛查参与者的各种生物样本(血浆、粪便和尿液)进行了调查。我们在血液、粪便和尿液样本中分别检测到了广泛的代谢物(分别为504种、331种和131种)。在血液与粪便、血液与尿液、粪便与尿液中的93种、154种和102种代谢物浓度之间发现了显著相关性,其中68种(73%)、126种(82%)和39种(38%)为正相关。我们发现,在血液、粪便和尿液样本中,晚期结直肠肿瘤患者与无肿瘤患者的123种、49种和28种代谢物浓度分别存在显著差异。我们在血液样本与尿液或粪便样本中的代谢物浓度之间大多检测到正相关,而在尿液和粪便样本之间大多检测到负相关。在三种生物流体中的每一种中,都发现了晚期结直肠肿瘤患者与无肿瘤患者之间代谢物浓度的差异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a075/8003917/400de5a39265/diagnostics-11-00561-g001.jpg

相似文献

2
Evaluation of different stool extraction methods for metabolomics measurements in human faecal samples.
BMJ Nutr Prev Health. 2021 Jul 2;4(2):374-384. doi: 10.1136/bmjnph-2020-000202. eCollection 2021.
3
Metabolomics Biomarkers for Detection of Colorectal Neoplasms: A Systematic Review.
Cancers (Basel). 2018 Jul 27;10(8):246. doi: 10.3390/cancers10080246.
4
Novel Stool-Based Protein Biomarkers for Improved Colorectal Cancer Screening: A Case-Control Study.
Ann Intern Med. 2017 Dec 19;167(12):855-866. doi: 10.7326/M17-1068. Epub 2017 Nov 21.
5
[Application study of stool-based methylated SDC2 test in the screening of colorectal neoplasms for physical examination population].
Zhonghua Yu Fang Yi Xue Za Zhi. 2022 Dec 6;56(12):1767-1773. doi: 10.3760/cma.j.cn112150-20220314-00233.
8
Asia-Pacific Colorectal Screening Score Combined With Stool DNA Test Improves the Detection Rate for Colorectal Advanced Neoplasms.
Clin Gastroenterol Hepatol. 2023 Jun;21(6):1627-1636.e4. doi: 10.1016/j.cgh.2022.09.002. Epub 2022 Sep 14.
10

引用本文的文献

1
Transfer RNA-derived small RNAs (tsRNAs): A rising star in liquid biopsy.
Genes Dis. 2025 Mar 19;12(5):101608. doi: 10.1016/j.gendis.2025.101608. eCollection 2025 Sep.
2
Potential of pre-diagnostic metabolomics for colorectal cancer risk assessment or early detection.
NPJ Precis Oncol. 2024 Oct 27;8(1):244. doi: 10.1038/s41698-024-00732-5.
3
Urine metabolomic profiles of autism and autistic traits-A twin study.
PLoS One. 2024 Sep 3;19(9):e0308224. doi: 10.1371/journal.pone.0308224. eCollection 2024.
5
Liquid biopsy techniques and pancreatic cancer: diagnosis, monitoring, and evaluation.
Mol Cancer. 2023 Oct 6;22(1):167. doi: 10.1186/s12943-023-01870-3.
6
cfOmics: a cell-free multi-Omics database for diseases.
Nucleic Acids Res. 2024 Jan 5;52(D1):D607-D621. doi: 10.1093/nar/gkad777.
7
Liquid Biopsies, Novel Approaches and Future Directions.
Cancers (Basel). 2023 Mar 3;15(5):1579. doi: 10.3390/cancers15051579.
8
9
Sex differences in the human metabolome.
Biol Sex Differ. 2022 Jun 15;13(1):30. doi: 10.1186/s13293-022-00440-4.
10
Use of Omics Technologies for the Detection of Colorectal Cancer Biomarkers.
Cancers (Basel). 2022 Feb 6;14(3):817. doi: 10.3390/cancers14030817.

本文引用的文献

1
Evaluation of different stool extraction methods for metabolomics measurements in human faecal samples.
BMJ Nutr Prev Health. 2021 Jul 2;4(2):374-384. doi: 10.1136/bmjnph-2020-000202. eCollection 2021.
5
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
6
Healthy Lifestyle Factors Associated With Lower Risk of Colorectal Cancer Irrespective of Genetic Risk.
Gastroenterology. 2018 Dec;155(6):1805-1815.e5. doi: 10.1053/j.gastro.2018.08.044. Epub 2018 Sep 8.
7
Metabolomics Biomarkers for Detection of Colorectal Neoplasms: A Systematic Review.
Cancers (Basel). 2018 Jul 27;10(8):246. doi: 10.3390/cancers10080246.
9
NMR-based metabolomics of biofluids in cancer.
NMR Biomed. 2018 Apr 19:e3927. doi: 10.1002/nbm.3927.
10
Urine: Waste product or biologically active tissue?
Neurourol Urodyn. 2018 Mar;37(3):1162-1168. doi: 10.1002/nau.23414. Epub 2018 Feb 21.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验